X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/caliway-announced-orphan-drug-designation-granted-to-cbl-514-for-the-treatment-of-dercums-disease-302077889.html
https://www.prnewswire.com/news-releases/caliway-received-us-fda-fast-track-designation-for-cbl-514-for-the-treatment-of-dercums-disease-302062403.html
https://www.prnewswire.com/news-releases/caliway-received-first-approval-of-cbl-514-pivotal-phase-3-study-application-for-subcutaneous-fat-reduction-302041781.html
https://www.prnewswire.com/news-releases/caliway-announces-fda-acceptance-of-cbl-514-ind-application-for-placebo-controlled-phase-2-study-to-treat-dercums-disease-302028040.html
https://www.prnewswire.com/news-releases/caliway-to-present-cbl-514-phase-2-study-results-for-subcutaneous-fat-reduction-at-imcas-2024-302022642.html
https://www.prnewswire.com/news-releases/caliway-closes-oversubscribed-capital-raise-and-secures-over-100m-to-advance-cbl-514-pivotal-phase-3-study-in-subcutaneous-fat-reduction-302017260.html
https://www.prnewswire.com/news-releases/caliways-cbl-514-achieved-better-efficacy-than-liposuction-reducing-over-300ml-of-subcutaneous-fat-on-average-in-cbl-0202-study-301944343.html
https://www.prnewswire.com/news-releases/caliway-announces-the-completion-of-subject-recruitment-in-the-cbl-0201efp-phase-2-stage-2-study-evaluating-the-cbl-514-in-cellulite-treatment-301931328.html
https://www.prnewswire.com/news-releases/caliway-announces-cbl-514-phase-2-study-topline-results-for-dercums-disease-showing-64-5-of-lipomas-with-complete-clearance-or-dimensions-reduction-of-over-50-and-reduced-pain-by-4-7--301925799.html
https://www.prnewswire.com/news-releases/caliway-announces-positive-data-from-cbl-0201efp-phase-2-stage-1-study-of-cbl-514-in-treating-moderate-to-severe-cellulite-301865567.html
Market Place
Share 
